Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy With Much Greater Sensitivity Than Dilated Ophthalmologist Exams
Academic leaders will report on their experience with the technology during a symposium at AAO 2022, the annual meeting of the American Academy of Ophthalmology
CHICAGO, September 30, 2022 /PRNewswire/ — At the 126th Annual Meeting of the American Academy of Ophthalmology (AAO 2022), Eyenuk, Inc., a global artificial intelligence (AI)-based digital health company and leading real applications for AI eye screening, announced the publication of fort eye art® validation results in Sciences of ophthalmologya peer-reviewed journal of the American Academy of Ophthalmology.
The study, titled “Artificial Intelligence Detection of Diabetic Retinopathy: Comparison of EyeArt System Subgroups with Dilated Ophthalmologist Exams,” evaluated general ophthalmologists, retina specialists and Eyenuk specialists. eye art AI system to detect diabetic retinopathy (DR), one of the leading causes of blindness in working-age adults.
Teacher Jennifer I. Lim MD, Vice President of Ophthalmology, UIC Emeritus Professor of Ophthalmology and Director of the Retina Service at University of Illinois at Chicago and the publication’s first author commented on the results: “Compared to reading center grading, which was the gold standard, the sensitivity for detecting more than mild DR was significantly higher with the eye art AI system than with a general ophthalmologist or clinical retinal examination specialist. Unlike a few cases where general ophthalmologists have missed some cases of vision-threatening diabetic retinopathy, the eye art The AI system did not miss any sight-threatening DR cases. The AI system is an important tool to help us deal with the burden of screening and detecting DR in a timely manner.”
The study assessed the sensitivity and specificity of the eye art ocular system and dilated examinations performed by general ophthalmologists and retina specialists against the rigorous clinical gold standard of the Early Treatment Diabetic Retinopathy Study (ETDRS) on the same cohort of 521 study participants. The ETDRS reference standard was established by experts from the University of Wisconsin Reading Center using 10 fundus images per eye captured after dilation by certified photographers, while the eye art The system only analyzed 2 images per eye, usually without dilation.
Sensitivity, a safety measure (percentage of patients with correctly identified disease), was 96.4% for the eye art system to identify more than mild DR (mtmDR), while that of dilated ophthalmologist exams was 27.7% on the same cohort of study participants. Specificity, a measure of effectiveness (percentage of patients with no disease identified correctly), was 99.6% by dilated ophthalmologist exams versus 88.4% with the eye art system. This result demonstrates that dilated examinations by ophthalmologists are more effective in excluding the disease, as evidenced by their high specificity. However, the EyeArt system, with its excellent sensitivity, is much better at identifying patients with the disease (at the first lines of care), a critical factor for a screening scenario in which patients are identified for referral and evaluation. further.
The study also reported that the eye art The system generated actionable results for over 97% of the eyes, with most (85.3%) not requiring dilation. In contrast, dilated exams provided usable results for 99.9% of eyes, but required all patients to be dilated.
Lim and his co-authors concluded the article by stating that, “Given the current low rate of compliance with the recommendation of an annual diabetic retinal examination, this system may be a useful adjunct in the detection of mtmDR and appears to be more accurate than clinical ophthalmoscopy for routine retinal screening.”
Since FDA clearance in 2020, the eye art The system is now used at more than 200 sites in 18 countries, including 14 US states, to screen more than 60,000 patients and counting. It is the first and only technology to be FDA cleared for the stand-alone detection of referable and vision-threatening diabetic retinopathy.
AAO 2022 Symposium to examine the actual results of using EyeArt
Eyenuk will showcase its cutting-edge AI technologies for diabetic eye screening at AAO 2022. October 2n/aEyenuk’s AI technologies will be showcased in a live AAO industry presentation symposium titled “Health System Adoption of FDA-Approved AI Technology for Diabetic Retinopathy Screening in Primary Care.”
Ophthalmology leaders from several academic medical centers will discuss their vision and progress in adopting Eyenuk’s AI technologies to improve diabetes eye care and population health.
The speakers of the symposium are:
- VR Paul Chan MD, MSc, MBA, FACS, Chair, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago
- Eric D. Hansen MD, assistant professor of ophthalmology and visual sciences, University of Utah
- Jeffrey D. Henderer MD, Director, Department of Ophthalmology, Lewis Katz School of medicine at Temple University
- Steven Yeh MD, President and Director, Retina and Uveitis, University of Nebraska Medical Center
The AAO Industry Showcase Symposium will take place on Sunday October 2n/a at 2:10 PM CT, at McCormick Place (booth #1026). Of October 1-3AAO 2022 attendees can see a demonstration of the eye art AI System and other Eyenuk technologies by visiting booth #2033.
About eye art AI system
The eye art AI System provides fully automated diabetic retinopathy (DR) screening, including retinal imaging, DR detection based on international clinical standards, and immediate notification, in a single office visit during regular examination of a diabetic patient. Once the patient’s fundus images have been captured and subjected to eye art AI System, DR detection results are available in a PDF report in less than 30 seconds.
The eye art AI System was developed with funding from the US National Institutes of Health (NIH) and is validated by the UK National Health Service (NHS). In addition to 510(k) clearance from the U.S. Food and Drug Administration (FDA), the eye art AI System has CE marking as a class 2a medical device in the European Union and a license from Health Canada. It is designed to be compliant with the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act of 1996 (HIPAA).
The eye art The system is reimbursed by government and private payers in the United States under the new Current Procedural Terminology (CPT) code 92229. Medicare began national coverage for CPT 92229 on January 1, 2021.
VIDEO: Learn more about the eye art AI system for autonomous detection of diabetic retinopathy
About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI)-based digital health company and the leader in real-world AI eye screening for autonomous disease detection and AI™ predictive biomarkers for risk assessment and disease surveillance. Eyenuk’s mission is to screen all eyes worldwide to ensure timely diagnosis of life-threatening and sight-threatening diseases including diabetic retinopathy, glaucoma, age-related macular degeneration, risk of stroke brain, cardiovascular risk and Alzheimer’s disease. Find Eyenuk online on its website, TwitterFacebook and LinkedIn.
Contact Eyenuk, Inc.
Frank ChengPresident & CCO
+1 818 835 3585
+1 510 417 0612